Zelira (ASX: ZLD) brings two new targeted medicinal cannabis medications to the market for Autism.
The Hope™ range is now available for prescription through Australia’s Special Access Scheme, and joins Zelira’s growing product range. The range is available now through Zelira’s distribution partner, Health House.
The products were first launched under licence to Elira Healthcare in Pennsylvania in 2019, who conducted a self-reported outcomes survey of 50 participants on the HOPE™ formulations for symptoms associated with Autism Spectrum Disorder. The survey found that 69% of patients showed improved quality of life.
The study follows two studies published in 2019 assessing the efficacy of medicinal cannabis for autism. The first found that 61% of patients using CBD rich medications showed improved behaviour, but with some notable side effects such as loss of appetite, sleep disorders and increased irritability in some cases. The second found that good quality of life was reported by 67% at the six-month assessment.
Autism is one of three indications Zelira is targeting, alongside chronic pain and insomnia.